This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gaily, E. Articles by Liukkonen, E. Search for Related Content PubMed PubMed Citation Articles by Gaily, E. Articles by Liukkonen, E. Social Bookmarking                         What's this?

Oxcarbazepine in the Treatment of Early Childhood Epilepsy

University of Helsinki, Hospital for Children and Adolescents, Neurology, Helsinki, Finland

Marja-Liisa Granström, MD

University of Helsinki, Hospital for Children and Adolescents, Neurology, Helsinki, Finland

Elina Liukkonen, MD

University of Helsinki, Hospital for Children and Adolescents, Neurology, Helsinki, Finland

Very little data are available on the usefulness of oxcarbazepine in young children with epilepsy. From January 1991 through October 1994, we treated 53 children under age 7 years with oxcarbazepine. The mean follow-up with oxcarbazepine treat ment was 13 months. Etiology was symptomatic in 39, cryptogenic in 12, and idiopathic in 2 children. Forty-three children had previously been intractable to one or more antiepileptic drugs (including carbamazepine in 30 patients) and two had carbamazepine hypersensitivity. The age at onset of oxcarbazepine therapy ranged from 0.6 to 6.9 years (mean, 3.9 yr). The mean maximum oxcarbazepine dose was 50 mg/kg/day (range, 21-86 mg/kg/day). Of the children with localization-related epilepsy, 12 of 44 (27%) became seizure free and an additional 16 of 44 (36%) had an at least 50% reduction of seizures. Five of nine children with generalized epilepsy also had some benefit but none became seizure free. In the 33 children with at least 50% seizure reduction, the mean effective dose and trough serum level of the active metabolite monohydroxycarbazepine were 47 mg/kg/day (range, 21-75 mg/kg/day) and 91 µmol/L (range, 42-130 µmol/L), respectively. Efficacy was transient in 4 children; side effects were observed in 17 children (32%); in 9 (17%) of whom, they led to dose reduction or discontinuation. Oxcarbazepine appears to be an effective and well-tolerated drug for localization-related early childhood epilepsy. Young children need a higher dose per body weight than adults. (J Child Neurol 1997;12:496-498).

Journal of Child Neurology, Vol. 12, No. 8, 496-498 (1997)
DOI: 10.1177/088307389701200806


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Rey, C. Bulteau, J. Motte, A. Tran, Y. Sturm, J. D'Souza, S. Markabi, G. Pons, and O. Dulac Oxcarbazepine Pharmacokinetics and Tolerability in Children With Inadequately Controlled Epilepsy J. Clin. Pharmacol., November 1, 2004; 44(11): 1290 - 1300. [Abstract] [Full Text] [PDF]

				J. W. Wheless and B. F. D. Bourgeois Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders J Child Neurol, August 1, 2004; 19(1_suppl): S39 - S48. [Abstract] [PDF]

				J. W. Wheless and B. F. D. Bourgeois Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders J Child Neurol, January 1, 2004; 19(1_suppl): S39 - S48. [Abstract] [PDF]

				J. W. Wheless Using the New Antiepilepsy Drugs in Children J Child Neurol, January 1, 2002; 17(1_suppl): S58 - S64. [Abstract] [PDF]

				T. A. Glauser, M. Nigro, R. Sachdeo, L. A. Pasteris, S. Weinstein, B. Abou-Khalil, L. M. Frank, A. Grinspan, T. Guarino, D. Bettis, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures Neurology, June 27, 2000; 54(12): 2237 - 2244. [Abstract] [Full Text] [PDF]